| Date:2021-June-16  |                                 |
|--|---------------------------------|
| Your Name: Diong Zhana   |                                 |
| Manuscript Title: PD-L1 Expression in Non-Small Cell Lung Cancer: Hete | erogeneity by Pathologic Types, |
| Tissue Sampling and Metastasis   |                                 |
| Manuscript number (if known): JTD-21-388                               | 3.865                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|      |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|------|--|--|--|
|      |  | Time frame: Since the initi  | al planning of the work  |
| 1    | All support for the present manuscript (e.g., funding,                           | _X_None  |  |
|      | provision of study materials,  |  |  |
|      | medical writing, article processing charges, etc.)  No time limit for this item. |  |  |
| 16.7 |  | 7 a  | of the second se |
|      |  | Time frame: pas  | t 36 months  |
| 2    | Grants or contracts from any entity (if not indicated in item #1 above).         | None   |  |
| 3    | Royalties or licenses  | _X_None  |  |
|      |  |  |  |
| 4    | Consulting fees  | None   |  |

| 5  | Payment or honoraria for   | X_None                                    |  |
|--|--|---|--|
|  | lectures, presentations,   |   | and the second   |
|  | speakers bureaus,  |   | THE TEACHER OF STREET  |
|  | manuscript writing or educational events   |   |  |
| 6  | Payment for expert   | √ None                                    |  |
|  | testimony  |   |  |
|  |  |   |  |
| 7  | Support for attending  | X_None                                    |  |
|  | meetings and/or travel   | 1 5 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 |  |
|  |  |   |  |
| *  |  |   |  |
| 8  | Patents planned, issued or   | X None                                    |  |
|  | pending  |   |  |
|  | the section of the se |   | A  |
| 9  | Participation on a Data  | X_None                                    |  |
| -50<br>-50<br>-50  | Safety Monitoring Board or<br>Advisory Board   | 243                                       |  |
| 10   | Leadership or fiduciary role   | X None                                    | A POST CONTRACTOR CONTRACTOR AND CON |
| 10   | in other board, society,   | Anone                                     |  |
|  | committee or advocacy  | Alabara and alabara                       |  |
| 141  | group, paid or unpaid  |   |  |
| 11   | Stock or stock options   | None                                      | Control of the Contro |
|  |  | 349                                       |  |
| 12   | Receipt of equipment,  | X_None                                    |  |
| 1000000 700  | materials, drugs, medical  |   |  |
|  | writing, gifts or other  |   |  |
| 13   | services Other financial or non-   | X None                                    |  |
| 13   | financial interests  | NONE                                      |  |
|  |  | MOSSING CONTROLS                          |  |
| The state of the s |  | 1000                                      |  |

| I certify that I | have answered every | question and have r | not altered th | ne wording o | f any of the | question | s on this |
|------------------|---------------------|---------------------|----------------|--------------|--------------|----------|-----------|
| form.            |                     |                     |                |              |              |          |           |

| Date:  |   |
|--|---|
| Your Name: ISI CHEN                                      |   |
| Manuscript Title: PD-L1 Expression in Non-Small Cell Lui | <u>ng Cancer: Heterogeneity by Pathologic Types</u> |
| Tissue Sampling and Metastasis                           |   |
| Manuscript number (if known):JTD-21-388                  |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|                      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----------------------|---|--|---|
| 6 (MR 1 (M 1) (MR 1) | 35,556-35-30-305-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1  | Time frame: Since the initia   | l planning of the work  |
| 1                    | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|                      |   | Time frame: past   | 36 months   |
| 2                    | Grants or contracts from any entity (if not indicated in item #1 above).  | _X_None  |   |
| 3                    | Royalties or licenses   | X None   |   |
| 4                    | Consulting fees   | None   |   |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None    |  |
|----|--|---------|--|
| 6  | Payment for expert<br>testimony  | None    |  |
| 7  | Support for attending meetings and/or travel   | None    |  |
| 8  | Patents planned, issued or pending   | None    |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | None    |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | _X_None |  |
| 11 | Stock or stock options   | None    |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | None    |  |
| 13 | Other financial or non-<br>financial interests   | None    |  |

| Date: 2021-June-16                              |   |
|---|---|
|   | C. II I Cargary Hotorogeneity by Pathologic Types,          |
| Manuscript Title: PD-L1 Expression in Non-Small | <u>Cell Lung Cancer: Heterogeneity by Pathologic Types,</u> |
| Tissue Sampling and Metastasis                  |   |
| Manuscript number (if known):JTD-21-388         |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|            |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments  (e.g., if payments were made to you or to your institution) |
|------------|---|--|--|
| 020502-000 | of production and a second  | Time frame: Since the initi  | al planning of the work  |
| 1          | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |  |
|            |   | Time frame: pas  | t 36 months  |
| 2          | Grants or contracts from any entity (if not indicated in item #1 above).  | X_None   |  |
| 3          | Royalties or licenses   | None   |  |
| 4          | Consulting fees   | None   |  |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None    |  |
|----|--|---------|--|
| 6  | Payment for expert<br>testimony  | None    |  |
| 7  | Support for attending meetings and/or travel   | None    |  |
| 8  | Patents planned, issued or pending   | None    |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | None    |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | _X_None |  |
| 11 | Stock or stock options   | None    |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | None    |  |
| 13 | Other financial or non-<br>financial interests   | None    |  |

| Date: <u>2021-Ju</u> | ne-16     |                                |                                 |                |
|----------------------|-----------|--------------------------------|---------------------------------|----------------|
| Your Name:           | yan       | (in                            |                                 |                |
| Manuscript Title     | : PD-L1 E | xpression in Non-Small Cell Lu | ng Cancer: Heterogeneity by Pat | hologic Types  |
| Tissue Samplin       | ng and Me | etastasis                      | -s cancer receiogenerty by rat  | nologic Types. |
| Manuscript num       |           |                                | _                               |                |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initi  | al planning of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | None   |   |
|   | medical writing, article processing charges, etc.)  No time limit for this item.     | 11. (2.1.)   |   |
|   |  |  |   |
|   |  | Time frame: pas  | st 36 months  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).             | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None    |  |
|----|--|---------|--|
| 6  | Payment for expert<br>testimony  | None    |  |
| 7  | Support for attending meetings and/or travel   | None    |  |
| 8  | Patents planned, issued or pending   | None    |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | None    |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | _X_None |  |
| 11 | Stock or stock options   | None    |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | None    |  |
| 13 | Other financial or non-<br>financial interests   | None    |  |

| Date: <u>2021-J</u> | une-16        |                  |                    |                      |            |                 |
|---------------------|---------------|------------------|--------------------|----------------------|------------|-----------------|
| Your Name:          | YING          | CHEN             |                    |                      |            |                 |
| Manuscript Tit      | le: PD-L1 Ex  | pression in Non- | Small Cell Lung Ca | ancer: Heterogeneity | by Patholo | ogic Types.     |
| Tissue Sampl        | ing and Met   | astasis          |                    |                      |            | 5814 - 1 k + 41 |
| Manuscript nu       | mber (if know | n):JTD-21-388    | 3                  |                      | S = 72     | A               |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|     |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|--|---|
|     |   | Time frame: Since the initi  | al planning of the work   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None   |   |
|     |   |  |   |
|     |   | Time frame: pas  | st 36 months  |
| 2 . | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3   | Royalties or licenses   | None   |   |
| 4   | Consulting fees   | None   |   |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None    |  |
|----|--|---------|--|
| 6  | Payment for expert<br>testimony  | None    |  |
| 7  | Support for attending meetings and/or travel   | None    |  |
| 8  | Patents planned, issued or pending   | None    |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | None    |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | _X_None |  |
| 11 | Stock or stock options   | None    |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | None    |  |
| 13 | Other financial or non-<br>financial interests   | None    |  |

| Date:2021-Jur     | ie-16         |                      | 100 1             |            |               |            |
|-------------------|---------------|----------------------|-------------------|------------|---------------|------------|
| Your Name:        | man           | Li                   |                   |            |               | 1.00       |
| Manuscript Title: | PD-L1 Exp     | ression in Non-Small | Cell Lung Cancer: | Heterogene | ity by Pathol | ogic Types |
| Tissue Samplin    | g and Metas   | stasis               |                   | 1 1 Au     |               |            |
| Manuscript num    | ber (if known | ): JTD-21-388        |                   |            |               | 100        |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   |  | Time frame: Since the initi  | al planning of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | None   |   |
|   | medical writing, article processing charges, etc.)  No time limit for this item.     | 2  |   |
|   |  |  |   |
|   |  | Time frame: pas  | t 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).             | _X_None  |   |
| 3 | Royalties or licenses  | <u>X</u> None  |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None         |  |
|----|--|--------------|--|
| 6  | Payment for expert<br>testimony  | None         |  |
| 7  | Support for attending meetings and/or travel   | None         |  |
| 8  | Patents planned, issued or pending   | None         |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | None         |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | _X_None      |  |
| 11 | Stock or stock options   | None         |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | <u></u> None |  |
| 13 | Other financial or non-<br>financial interests   | None         |  |

| Date: <u>2021-June-16</u>        |                           | · ·                    |                         |
|----------------------------------|---------------------------|------------------------|-------------------------|
| Your Name: Yue Wana              |                           |                        |                         |
| Manuscript Title: PD-L1 Expressi | ion in Non-Small Cell Lur | ng Cancer: Heterogenei | ty by Pathologic Types. |
| Tissue Sampling and Metastasi    |                           | v v                    |                         |
| Manuscript number (if known):    | JTD-21-388                |                        | and the second          |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| į |   | Name all entities with<br>whom you have this<br>relationship or Indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initia   | l planning of the work  |
| 1 | All support for the present manuscript (e.g., funding,                          | None   |   |
|   | provision of study materials,   |  |   |
|   | medical writing, article processing charges, etc.) No time limit for this item. |  |   |
|   |   |  |   |
|   |   | A  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from  | X_None   |   |
|   | any entity (if not indicated in item #1 above).                                 |  |   |
| 3 | Royalties or licenses   | X_None   | HOLE AND CONTRACT TO A SECURITION OF THE SECOND                                     |
|   |   | 是这样。这种对象的一种理解。   |   |
|   | Control of the Control of the Control   | Mary Marie Marie Marie Constant  |   |
| 4 | Consulting fees   | _X_None  |   |
| 1 |   |  |   |

| 5  | Payment or honoraria for  | X_None   |  |
|--|---|--|--|
|  | lectures, presentations,  |  | and the second second second second second second second   |
|  | speakers bureaus,   |  | THE RESERVE TO A SUMMER OF THE PARTY.  |
|  | manuscript writing or educational events  |  |  |
| 6  | Payment for expert  | √ None   | AND DESCRIPTION OF THE PROPERTY OF THE PROPERT |
|  | testimony   |  |  |
|  |   |  |  |
| 7  | Support for attending   | X_None   |  |
|  | meetings and/or travel  | 1 5 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6  |  |
|  |   | 13.4.00 x,   |  |
|  |   | A STATE OF THE STA |  |
| 8  | Patents planned, issued or  | X None   |  |
|  | pending   |  |  |
|  |   |  | 2  |
| 9  | Participation on a Data   | <u>X</u> None  |  |
|  | Safety Monitoring Board or  |  |  |
| 10   | Advisory Board  Leadership or fiduciary role  | X None   |  |
| 10   | in other board, society,  | None   |  |
|  | committee or advocacy   |  |  |
|  | group, paid or unpaid   |  | The second secon |
| 11   | Stock or stock options  | None   |  |
|  |   |  |  |
| 12   | Receipt of equipment,   | X_None   |  |
| Attuation 1956   | materials, drugs, medical   |  |  |
|  | writing, gifts or other   |  |  |
| 13   | services Other financial or non-  | X None   |  |
| 13   | financial interests   | None   |  |
|  | municipi intereses  |  |  |
| THE PARTY OF THE P | BACKET AND AND COMPANY OF THE PROPERTY OF THE |  |  |

| I certify that I | have answered every | question and have | not altered the | ne wording o | f any of the | question | s on this |
|------------------|---------------------|-------------------|-----------------|--------------|--------------|----------|-----------|
| form.            |                     |                   |                 |              |              |          |           |